Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kamada-AAT for inhalation versus placebo in adults with alpha-1 antitrypsin deficiency-related lung disease
NL-OMON55372Phase 3Recruiting
- Sponsor
- Kamada Ltd.
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha1-proteinase inhibitor (human) in alpha-1 antitrypsin deficiency (AATD) and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Kamada Ltd. Primary endpoints: Post-bronchodilator FEV1 change from baseline at 104 weeks, Post-bronchodilator FEV1 change at total 208 weeks and OLE 104 weeks and 5 more. Started Oct 2019; status: recruiting.
02
Drugs
alpha1-proteinase inhibitor (human)
03
Conditions
alpha-1 antitrypsin deficiency (AATD)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON55372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55372.